Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.66 |
| ▸ | APLNR | P35414 | 2/20 | 0.63 |
| ▸ | TFPI | P10646 | 4/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | NPY4R | P50391 | 5/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.57 |
| ▸ | NPY1R | P25929 | 4/20 | 0.57 |
| ▸ | GLP1R | P43220 | 3/20 | 0.55 |
| ▸ | GCGR | P47871 | 3/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525147 | 0.94 | APLNR (0.63) | APLNRTFPINPY2RNPY4RNPY5R | |
| SCHEMBL18787566 | 0.94 | APLNR (0.61) | GHSRAPLNRTFPINPY2RNPY4R | |
| SCHEMBL31656374 | 0.93 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29526390 | 0.92 | APLNR (0.64) | APLNRTFPINPY2RNPY4RNPY5R | |
| SCHEMBL30166497 | 0.92 | APLNR (0.62) | GHSRAPLNRTFPINPY2RNPY4R | |
| SCHEMBL29525492 | 0.92 | APLNR (0.64) | GHSRAPLNRTFPI | |
| SCHEMBL29526046 | 0.91 | APLNR (0.64) | GHSRAPLNRTFPINPY2RNPY4R | |
| SCHEMBL29525577 | 0.91 | APLNR (0.64) | GHSRAPLNRTFPINPY2RNPY4R | |
| SCHEMBL5498547 | 0.91 | APLNR (0.60) | GHSRAPLNRTFPINPY2RNPY4R | |
| SCHEMBL16150700 | 0.88 | APLNR (0.64) | GHSRAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404609-A1 | Systems and Methods for Duodenal Mucosal Resection | SHARMA VIRENDER K (US) | 2023-12-21 | — | — | US | claimed |
| WO-2023225675-A2 | SYSTEMS AND METHODS FOR DUODENAL MUCOSAL RESECTION | SHARMA VIRENDER K (US) | 2023-11-23 | — | — | WO | claimed |
| US-11806066-B2 | Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems | Aqua Medical, Inc. | 2023-11-07 | — | — | US | claimed |
| US-12564435-B2 | Multi-dose duodenal ablation through an endoscope | Aqua Medical, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4635435-A2 | MULTI-STAGE VAPOR-BASED ABLATION TREATMENT METHODS AND VAPOR GENERATION AND DELIVERY SYSTEMS | Aqua Medical, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302522-A1 | Multi-Dose Duodenal Ablation Through an Endoscope | Aqua Medical, Inc. | 2025-10-02 | — | — | US | disclosed |
| US-20250302521-A1 | Duodenal Ablation with Improved Depth and Consistency of Ablation | Aqua Medical, Inc. | 2025-10-02 | — | — | US | disclosed |
| EP-3801324-B1 | VAPOR GENERATION AND DELIVERY SYSTEMS | AQUA MEDICAL INC (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119947666-A | Systems and methods for duodenal mucosal resection | 维伦德·K·夏尔马 | 2025-05-06 | — | — | CN | disclosed |
| US-12279803-B2 | Vapor-based ablation treatment methods with improved treatment volume vapor management | Aqua Medical, Inc. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240398462-A1 | Duodenal Ablation with Improved Depth and Consistency of Ablation | Aqua Medical, Inc. | 2024-12-05 | — | — | US | disclosed |
| US-11712562-B2 | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy | ELIRA INC (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4211635-A1 | ELECTRICAL STIMULATION-BASED WEIGHT MANAGEMENT SYSTEM | Elira, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220362556-A1 | Systems and Methods for Enabling Appetite Modulation and/or Improving Dietary Compliance Using Percutaneous Electrical Neurostimulation | Elira, Inc. | 2022-11-17 | — | — | US | disclosed |
| CN-115227969-A | Method for achieving appetite regulation or improving dietary compliance using electrode patches | 伊莱拉股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-108271363-B | System and method for achieving appetite regulation and/or improving dietary compliance using electrode patches | 伊莱拉股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11369501-B2 | Percutaneous electrical dermal patch for enabling appetite modulation and/or improving dietary compliance | Elira, Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220133382-A1 | Vapor-Based Ablation Treatment Methods with Improved Treatment Volume Vapor Management | Aqua Medical, Inc. | 2022-05-05 | — | — | US | disclosed |
| WO-2022056539-A1 | ELECTRICAL STIMULATION-BASED WEIGHT MANAGEMENT SYSTEM | Elira, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220062621-A1 | Electrical Stimulation-Based Weight Management System | ELIRA INC (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564435-B2 | Multi-dose duodenal ablation through an endoscope | SLC10A2, TTK, FABP2 | GHSR 771/4885APLNR 1816/4885TFPI 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.